Skip to main content
. 2013 Sep 6;3(9):e145. doi: 10.1038/bcj.2013.44

Figure 3.

Figure 3

Clinical responders to K562/GVAX vaccination make novel high-titer IgG responses to a broad range of LAAs. (a) Residual CML disease burden as determined by BCR–ABL values as determined by RQ-PCR from patient PBMC mRNA before and after vaccination (vertical dashed line represents primary J0345 vaccination series). (b) Number of LAAs recognized by serum IgG in each patient before (‘pre') and after primary vaccination (time on x axis in days). (c) Quantitative measurement of LAA-specific serum IgG. Maximal ‘titer' of induced responses was observed between day 42 and 84 time points (that is, 6–12 weeks). Normalized intensity is color-coded (lower limit of detection, 0.083 in dark blue, maximal in red) according to the scale in Figure 4a.